Huijing Wu
A5009583844- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- PI3K/AKT/mTOR signaling in cancer
- Viral-associated cancers and disorders
- CAR-T cell therapy research
- Bone health and treatments
- Advanced Breast Cancer Therapies
- Chronic Myeloid Leukemia Treatments
- Radiopharmaceutical Chemistry and Applications
- Cutaneous lymphoproliferative disorders research
- Multiple Myeloma Research and Treatments
Hubei Cancer Hospital
2023-2024
Abstract Anti-PD-1 antibodies are a favorable treatment for relapsed or refractory extranodal natural killer T cell lymphoma (RR-ENKTL), however, the complete response (CR) rate and duration of (DOR) need to be improved. This phase 1b/2 study investigated safety efficacy sintilimab, fully human anti-PD-1 antibody, plus chidamide, an oral subtype-selective histone deacetylase inhibitor in 38 patients with RR-ENKTL. Expected objective (ORR) combination was 80%. Patients received escalating...
Abstract Purpose: To investigate the efficacy and safety of novel orally active PI3Kδ inhibitor in relapsed and/or refractory patients with follicular lymphoma (FL) who had received at least two prior systemic treatments. Patients Methods: Histologically confirmed FL disease progression after receiving second-line or greater therapy were enrolled. Linperlisib was administered 80 mg every day, a 28-day cycle until intolerable toxicity occurred. The primary outcome for study objective response...
Importance The bioequivalence of denosumab biosimilar has yet to be studied in a 53-week, multicenter, large-scale, and head-to-head trial. A clinically effective may help increase access patients with solid tumor–related bone metastases. Objectives To establish the biosimilarity MW032 metastases based on large-scale study. Design, Setting, Participants In this randomized, double-blind, phase 3 equivalence trial, tumors metastasis were recruited from 46 clinical sites China. Overall, 856...
<div>AbstractPurpose:<p>To investigate the efficacy and safety of novel orally active PI3Kδ inhibitor in relapsed and/or refractory patients with follicular lymphoma (FL) who had received at least two prior systemic treatments.</p>Patients Methods:<p>Histologically confirmed FL disease progression after receiving second-line or greater therapy were enrolled. Linperlisib was administered 80 mg every day, a 28-day cycle until intolerable toxicity occurred. The primary...
<p>Subgroup analysis of (A) ORR, (B) DOR and (C) PFS confirmed by investigator</p>
<p>Comparison of the concentrations serum markers measured in patients with and without a response to linperlisib</p>
<p>Serum cytokine concentrations before and during treatment</p>
<p>Subgroup analysis of (A) ORR, (B) DOR and (C) PFS confirmed by investigator</p>
<p>Comparison of the concentrations serum markers measured in patients with and without a response to linperlisib</p>
<p>Serum cytokine concentrations before and during treatment</p>
<div>AbstractPurpose:<p>To investigate the efficacy and safety of novel orally active PI3Kδ inhibitor in relapsed and/or refractory patients with follicular lymphoma (FL) who had received at least two prior systemic treatments.</p>Patients Methods:<p>Histologically confirmed FL disease progression after receiving second-line or greater therapy were enrolled. Linperlisib was administered 80 mg every day, a 28-day cycle until intolerable toxicity occurred. The primary...
<div>AbstractPurpose:<p>To investigate the efficacy and safety of novel orally active PI3Kδ inhibitor in relapsed and/or refractory patients with follicular lymphoma (FL) who had received at least two prior systemic treatments.</p>Patients Methods:<p>Histologically confirmed FL disease progression after receiving second-line or greater therapy were enrolled. Linperlisib was administered 80 mg every day, a 28-day cycle until intolerable toxicity occurred. The primary...